Social determinants of drug-susceptible and drug resistant tuberculosis Source: International Congress 2016 – Epidemiological insights into tuberculosis pathogenesis Year: 2016
Do we need to screen for latent TB when initiating a methotrexate treatment? Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection: diagnosis and treatment Year: 2013
Impact of social support programme on MDR-TB patients' treatment outcomes Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 3 Year: 2014
The European union standards for tuberculosis care: Do they need an update? Source: International Congress 2014 – Tuberculosis: public health and primary prevention Year: 2014
The top of the iceberg - Extensively drug resistant tuberculosis (XDR-TB) in 2010 Source: International Congress 2015 – Epidemiology of TB: deaths, co-morbidities, migration and children Year: 2015
Home based tuberculosis (TB) care program Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 1 Year: 2014
Latent TB infection: Patient choices and completion of treatment Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics Year: 2016
MDR TB treatment results of GFATM program implementation in Tomsk, Russia Source: International Congress 2015 – Management of TB: a patient focus Year: 2015
Drug resistance among new TB cases in some Russian regions Source: International Congress 2015 – Epidemiology of TB: deaths, co-morbidities, migration and children Year: 2015
Is it necessary to give tuberculosis treatment daily throughout? Source: International Congress 2014 – Mycobacterium tuberculosis infection and disease: clinical epidemiology 1 Year: 2014
Restarting biologic agents in rheumatology patients who developed tuberculosis under TNFα-inhibitor treatment Source: International Congress 2015 – Latent TB infection and screening Year: 2015
Four cases, one family: A cluster of resistant tuberculosis Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Estimating costs for treating patients with multi-drug resistant tuberculosis (MDR TB) under the regional tuberculosis control program, Tomsk (Russia) Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015
Impact of drug injection using on TB-AIDS treatment outcomes Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management I Year: 2013
Delay in pulmonary tuberculosis treatment in Croatia Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013
Liver injury in treatment of latent tuberculosis infection - is the age cut-off for treatment justified? Source: International Congress 2014 – Mycobacterium tuberculosis infection: new therapeutic approaches Year: 2014
The global response to rifampicin-resistant tuberculosis: Current situation and recent trends Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016
Tuberculosis and HIV infection in combination with multidrug resistant MBT on Northwest of Russia Source: International Congress 2016 – Epidemiological aspects of tuberculosis and other respiratory conditions: from lung cancer to late-onset Pompe's disease Year: 2016
Prospects for early implementation of ambulatory treatment in XDR TB patients by optimizing the administration of linezolid at the intensive phase of chemotherapy Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
The particularities of new cases of tuberculosis at homeless people Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management II Year: 2013